

Contents

Part I Introduction 1

1	Chronology of Drug Development for Malaria	3
	<i>Nalini Kurup and Nikhil Rajnani</i>	
1.1	Introduction	3
1.1.1	Life Cycle of Malaria (Adapted from CDC)	4
1.2	Malaria – Erstwhile Memories	5
1.2.1	Progress Fighting Malaria	5
1.3	Current Chemotherapy Used to Treat Malaria	7
1.3.1	Current Combination Therapy	13
1.4	Drug Resistance of Antimalarial Drugs	14
1.4.1	Detection of Drug Resistance	16
1.5	Newer Drugs Approved for Malaria Treatment	17
1.6	Current Approaches to Developing a Malaria Vaccine	18
1.6.1	Hope for Vaccine Lies in the Parasite Itself	18
1.7	Conclusion: The Path Forward	20
1.7.1	RTS, -S Vaccine: A New Tool with Potential for Africa	20
	References	21

Part II Challenges and Opportunities in Malaria Therapy 25

2	Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology	27
	<i>Ketaki Ramani</i>	
2.1	Introduction	27
2.2	The Scientific Challenges Against Malarial Drug	28
2.3	Advances in Understanding and Managing Drug Resistance	29
2.3.1	Vector and Its Control	29
2.3.2	Parasite and Its Control	30
2.3.2.1	Malaria Vaccine	31
2.3.2.2	Antimalarial Drugs	31

2.4	Methods to Assess the Presence and Level of Drug Resistance	32
2.4.1	Therapeutic Efficacy of Antimalarial Drugs	32
2.4.2	Molecular Markers Associated with <i>P. falciparum</i>	33
2.5	Antimalarial Drugs Currently in Use and in the Pipeline	33
2.6	Future	38
	References	40

3 Emerging Formulation Technologies Against Malaria

Resurgence 45

Kinjal Parikh, Rakhee Kapadia, Rohan Pai, Mahendra Prajapati, and Ganesh Shevalkar

List of Abbreviations 45

3.1	Introduction	46
3.1.1	Major Pathological Hallmarks of Malaria	46
3.1.2	Current Treatment Strategies	47
3.2	Pitfalls of the Current Treatment Regimen	47
3.2.1	Drug Resistance	47
3.2.2	High Drug Dose	48
3.2.3	Long-Term Treatment	48
3.2.4	Recurrence and Reversion of Diseases	48
3.3	Nanotechnology-Based Strategies for Targeting in Antimalarial Therapy	49
3.3.1	Passive Targeting	49
3.3.2	Active Targeting	49
3.3.2.1	Hepatocyte Targeting	50
3.3.2.2	Erythrocyte Targeting	50
3.3.2.3	Brain Targeting	50
3.3.3	Rapid Diagnosis and Vector Control	51
3.4	Nano Formulations for Malarial Treatment	51
3.4.1	Lipid-Based Nanoplatfroms	52
3.4.1.1	Nanoemulsion	52
3.4.1.2	Self-Emulsifying Drug Delivery System (SEDDS)	53
3.4.1.3	Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)	54
3.4.1.4	Liposome	54
3.4.2	Polymer-Based Nanoplatfroms for Malaria	55
3.4.2.1	Nanoparticles	55
3.4.2.2	Nanocapsules	58
3.4.2.3	Dendrimers	58
3.4.2.4	Micelles	59
3.4.2.5	Polymeric Hydrogel Nanoparticles	59
3.4.2.6	Nanosuspension	59
3.4.3	Organized Layer-by-Layer Assembly	59
3.4.4	Inorganic Nano-architectonics	59
3.4.4.1	Metallic Platforms	60

3.4.4.2	Quantum Dots	61
3.4.4.3	Carbon Nanostructures	62
3.4.4.4	Bio-ceramics	62
3.4.5	Bio-inspired Nanocarriers	63
3.4.5.1	Vaccines Based on Bio-inspired Nanocarriers	63
3.4.5.2	Bio-engineered Strategy Based on Erythrocytes	64
3.4.6	Protein–Peptide-Based Drug Delivery System	64
3.4.7	Stimuli-Responsive Platforms for Malaria	64
3.4.7.1	pH-Responsive Formulations	65
3.4.7.2	Thermo-Responsive Formulations	65
3.4.7.3	Redox State Responsive Substances	65
3.4.7.4	Stimuli-Responsive Liquid Crystalline Materials	65
3.5	Diagnostics	66
3.5.1	Stimuli-Responsive Iron Oxide and Gold Nanoparticle Reagent System	66
3.5.2	Immunological Adjuvants	66
3.5.3	Nanofibers	66
3.6	Challenges in Clinical Translation of Nanomedicine	67
3.6.1	Biological Challenges	67
3.6.2	Biocompatibility and Safety	67
3.6.3	Challenges in Manufacturing Scale-Up and Reproducibility	67
3.6.4	Analytical Characterization and Quality Control Challenges of Nano-Formulations	68
3.6.5	Regulatory Challenges	68
3.6.6	Other Challenges	69
3.7	Summary and Future Perspective	69
3.8	Conclusion	69
	Acknowledgments	70
	References	70
4	Targeted Drug Delivery for Antimalarial Therapy	83
	<i>Suha Zwayen, Tamara Zwain, and Kamalinder K. Singh</i>	
4.1	Introduction	83
4.2	Remodelling of Parasite-Infected Red Blood Cell (pRBC)	84
4.2.1	The Red Blood Cell Membrane (RBCM)	85
4.2.2	The Parasitophorous Vacuole Membrane (PVM)	85
4.2.3	The Parasite Plasma Membrane (PPM)	86
4.3	The Emergence of Resistance and Antimalarial Therapy Approach	86
4.4	Nanocarriers for Antimalarial Drug Delivery	89
4.4.1	Liposomes	89
4.4.2	Solid Lipid Nanoparticles (SLNs)	91
4.4.3	Nanostructured Lipid Carriers (NLCs)	91
4.4.4	Nano-emulsions (NEs)	91
4.4.5	Polymeric Nanoparticles	92
4.5	Targeted Antimalarial Drug Delivery Systems	92

4.5.1	Passive Drug Targeting with Conventional Nanocarriers	92
4.5.2	Active Drug Targeting with Surface-Modified Nanocarrier	93
4.6	Conclusion: Moving Towards the Future	97
	Acknowledgements	97
	References	97
5	The Imminent Threat of Antimalarial Drug Resistance	105
	<i>Bharti Singal and Jyoti Chhibber-Goel</i>	
5.1	Introduction	105
5.2	Antimalarial Drugs: An Overview	107
5.3	The Evolution of CQ Resistance	109
5.3.1	Mechanism of Action of CQ	109
5.3.2	Basis of CQ Resistance	110
5.3.3	Prevalence of CQ Resistance	112
5.3.4	WHO Guidelines to Use CQ	113
5.4	Impact of Sulfadoxine–Pyrimethamine Resistance	113
5.4.1	Mechanism of Action of SP	114
5.4.2	SP Resistance	116
5.4.3	Distribution of DHPS and DHFR Mutation Across Globe	117
5.4.3.1	<i>dhfr</i>	117
5.4.3.2	<i>dhps</i>	117
5.4.4	WHO Guidelines to Use SP	118
5.4.4.1	IPTp Guidelines	118
5.4.4.2	IPTi Guidelines	118
5.5	ACT Resistance	118
5.5.1	Mechanism of Action of ART	121
5.5.2	ART Resistance and ACT Failure	122
5.5.3	WHO Guidelines	123
5.6	Conclusion: The Road Ahead	124
	References	124
6	Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria	133
	<i>Pooja Mittal and Rupesh K. Gautam</i>	
6.1	Introduction	133
6.2	Life Cycle of <i>Plasmodium falciparum</i>	134
6.3	Current Antimalarial Therapy and Their Shortcomings	134
6.4	Drug Targets for Current Antimalarial Therapy	136
6.4.1	Drug-Resistant Malaria and Identification of New Targets	137
6.4.1.1	Food Vacuole as Drug Targets	137
6.4.1.2	Shikimic Acid Pathway Targeting	142
6.4.1.3	Targeting Folate Pathway and Methionine Synthesis Pathway	142
6.4.1.4	Glycolytic Pathway Inhibition	144
6.4.2	Mitochondria as Drug Targets	144

6.4.2.1	Targeting Electron Transport Chain	144
6.4.2.2	Inhibition of Dihydroorate Dehydrogenase	144
6.5	Future Drug Development for the Treatment of Malaria	146
6.5.1	Benefits of Nanocarriers	146
6.5.2	Lipid-Based Drug Delivery	146
6.5.3	Liposomes (as Nanocarriers)	146
6.5.4	Nanostructured Lipid Carriers	146
6.5.5	Solid Lipid Nanocarriers	147
6.6	Conclusion	147
	References	147

Part III Drug Development 151

7	Assays for Antimalarial Drug Discovery	153
	<i>Varun Gorki, Neha S. Walter, and Sukhbir Kaur</i>	
7.1	Introduction	153
7.2	<i>In Vitro</i> Assays for Antimalarial Drug Discovery	155
7.2.1	Schizont Maturation Inhibition Assay (Microscopic Test)	156
7.2.2	<i>In Vitro</i> Micro Test Technique	156
7.2.3	Radioisotope Assay	156
7.2.4	Colorimetric Assay (Plasmodium Lactate Dehydrogenase Assay [pLDH])	157
7.2.5	ELISA-Based Methods	157
7.2.5.1	DELI Assay	157
7.2.5.2	Assay Based on Histidine-Rich Protein II (HRP II) of <i>P. falciparum</i>	158
7.2.6	Flow Cytometry	158
7.2.7	Fluorometric Assay	158
7.2.8	β -Hematin Formation (Haemozoin Test)	159
7.2.9	Drug Interaction Assay and Isobologram Analysis	159
7.2.10	PCR-Based Methods	160
7.2.11	<i>In Vitro</i> Assays Targeting Exo-erythrocytic and Sexual Stages of the Parasite	160
7.2.11.1	Exo-erythrocytic Schizontocidal Assay	160
7.2.11.2	Ex-flagellation Assay	160
7.3	<i>In Vivo</i> Assays for Antimalarial Drug Discovery	161
7.3.1	Peters' 4-Day Test	162
7.3.2	Dose Ranging Full 4-Day Test	163
7.3.3	Onset/Recrudescence Test	163
7.3.4	Preventive Test	166
7.3.5	Curative Test	166
7.3.6	Hill's Test for Causal Prophylaxis and Residual Activity	166
7.3.7	Assays with <i>P. berghei</i> Green Fluorescent Protein (PbGFP)	167
7.3.8	Assays Employing Immunocompromised Mice	167

7.3.9	Primate Models for <i>In Vivo</i> Studies	168
7.3.10	Sporontocidal Assays	169
7.3.11	Anti-sporozoite Assay	169
7.4	<i>Ex Vivo</i> Assays for Antimalarial Drug Discovery	169
7.5	Assays for Assessment of <i>In Vitro</i> Toxicity	170
7.5.1	MTT Assay	170
7.5.2	XTT Assay	172
7.5.3	LDH (Lactate Dehydrogenase) Assay	172
7.5.4	Protein Content Assay	173
7.5.5	Neutral Red Uptake Assay (NRU)	173
7.6	Assays for Assessment of <i>In Vivo</i> Toxicity	173
7.6.1	Acute Toxicity	174
7.6.1.1	Limit Test of Lorke	175
7.6.1.2	Up and Down Procedure	175
7.6.2	Chronic Toxicity	175
7.7	Conclusion	176
	References	177
8	Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective	187
	<i>Bharti Singal and Jyoti Chhibber-Goel</i>	
8.1	Introduction	187
8.2	<i>Pf/Pv</i> -aaRSs	188
8.2.1	<i>Pf/Pv</i> Genome	188
8.2.2	Aminoacyl-tRNA Synthetases (aaRSs)	189
8.3	Aminoacyl-tRNA Synthetases as Druggable Targets	190
8.4	Biochemical Screening of Drug Libraries	192
8.4.1	Colorimetric Assays	192
8.4.2	Enzyme-Coupled Assays	193
8.4.3	Luciferase Assay	193
8.4.4	Assay to Test Synthetic as Well as Proofreading Activity	193
8.5	Structurally Validated <i>Pf/Pv</i> -aaRSs as Drug Targets	194
8.5.1	Lysyl-tRNA Synthetase (KRS)	194
8.5.2	Prolyl-tRNA Synthetase	197
8.6	Potential Drug Targets <i>Pf/Pv</i> -aaRSs	199
8.6.1	Leucyl-tRNA Synthetase (LRS)	199
8.7	Arginyl-tRNA Synthetase (RRS)	199
8.7.1	Tryptophanyl-tRNA Synthetase (WRS)	201
8.7.2	Tyrosyl-tRNA Synthetase	202
8.8	Others	203
8.9	Conclusion: The Road Ahead	203
	References	204

9	Natural Products as a Source for Antimalarial Drug Development Process – An Overview	213
	<i>Uma R. Lal and Snigdha Lal</i>	
9.1	Introduction	213
9.2	Phytochemicals as Antimalarial Agents: Recent Developments	214
9.2.1	Alkaloids	214
9.2.2	Terpenes	219
9.2.2.1	Sesquiterpene Lactones	219
9.2.2.2	Diterpenes	220
9.2.2.3	Triterpenes	222
9.2.2.4	Steroids and Others	224
9.2.3	Polyphenols	224
9.2.3.1	Biflavonoids	224
9.2.3.2	Prenylated Flavonoids	226
9.2.3.3	Other Flavonoids	226
9.3	Traditional System of Medicine and Malaria	227
9.3.1	Plants/Formulations Used in Malaria Treatment in Ayurvedic System of Medicine	227
9.4	Conclusions	228
	References	228
10	Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review	235
	<i>Senzosenkosi S. Mkhize, Kgothatso E. Machaba, Mthokozisi B. C. Simelane, and Ofentse J. Poole</i>	
10.1	Introduction	235
10.2	Biological Roles of Mushrooms	235
10.2.1	Malarial History and Impact	235
10.2.2	Antimalarial Activity of Mushroom Extracts	237
10.2.3	Bioactive Molecules Found Within Mushrooms	239
10.2.4	Phytochemical Properties of Mushroom Derived Antimalarial Products	241
10.2.5	Immunomodulatory Properties of Mushrooms	243
10.3	Conclusion	243
	Acknowledgements	244
	References	244
11	Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials	251
	<i>Meenakshi Jain, Samarpita Das, and Rahul Jain</i>	
11.1	Introduction	251
11.1.1	History	251

11.1.2	Mode of Action	253
11.1.3	SAR of Aminoquinolines	255
11.1.3.1	SAR of 8-Aminoquinolines	255
11.1.3.2	SAR of 4-Aminoquinolines	257
11.2	Synthetic Approaches of 8-Aminoquinolines and 4-Aminoquinolines	259
11.2.1	Synthetic Approach of 8-Aminoquinolines	259
11.2.1.1	Synthetic Approach of Well-Established Drugs	259
11.2.1.2	Synthetic Approach of Recently Developed PQ Congeners	269
11.2.2	Synthetic Approaches of 4-Aminoquinolines	270
11.2.2.1	Synthetic Approaches to Well-Established Drugs	270
11.2.2.2	Synthetic Approach of PQ–CQ Hybrid	280
11.3	Conclusion and Future Perspectives	280
	Acknowledgment	281
	References	281
12	Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1,3,4-Oxadiazole Moiety	285
	<i>Vinayak Adimule, Adarsha Haramballi Jagadeesha Gowda, Santosh S. Nandi, and Debdas Bowmik</i>	
12.1	Introduction	285
12.1.1	Materials and Methods	286
12.1.2	Synthesis	287
12.2	Experimental Procedure for <i>In Vitro</i> Studies on Antimalarial Activity	287
12.2.1	Experimentation	289
12.2.1.1	Analytical Results of the Intermediate Compounds (6a–10a)	289
12.3	Analytical Results of Intermediate Compounds (12–16)	290
12.3.1	NMR and CMR Analysis	290
12.4	Synthesis Procedures for 4-Ethoxy Phenyl Boronic Acid (General Procedure for Compounds 2 , 3 , and 4)	292
12.4.1	Synthesis of 1-Bromo-4-(Cyclopropyl Methyl) Benzene (Compound 2)	292
12.4.1.1	1-Bromo-4-(Cyclopentyl Methoxy)Benzene (Compound 2b)	292
12.4.1.2	1-Bromo-4-(Cyclohexyl Methoxy)Benzene (Compound 2c)	292
12.4.1.3	1-(Benzyloxy)-4-Bromobenzene (Compound 2d)	293
12.4.1.4	1-Bromo-4-(Pentyloxy) Benzene (Compound 2e)	293
12.4.1.5	Synthesis of 4-Methoxy Phenyl-Bispinacolato Adduct (3a)	293
12.4.1.6	Synthesis of 4-Methoxy Phenyl Boronic Acid	293
12.4.1.7	General Procedure for the Synthesis of Derivatives (Compounds 6–10) (Step II)	293
12.4.1.8	General Procedure for the Synthesis of Derivatives (Compounds 6a–10a)	293
12.4.1.9	General Procedure for the Synthesis of Derivatives (Compounds 12–16)	294

12.5	Results and Discussion	294
12.5.1	<i>In Vitro</i> Antiplasmodial Activity	294
12.6	Conclusion	297
	Authors Contributions	298
	Acknowledgments	298
	Conflict of Interest	298
	References	298

Part IV A Vaccine Perspective 303

13	Recent Advances in Malaria Vaccine Development	305
	<i>Sailendra Kumar Mahanta</i>	
13.1	Introduction	305
13.2	History of Malaria Vaccine Development	306
13.3	Vaccine Design Targets and Approaches	308
13.4	Types of Malaria Vaccine	309
13.4.1	Pre-erythrocytic Vaccines	309
13.4.1.1	Vaccines Based on the RTS, -S, and CSP Encoded Sections of the Malaria Gene	310
13.4.2	Whole Sporozoite Vaccines	311
13.4.3	Blood Stage Vaccines (BSVs)	311
13.4.4	Placental Malaria Vaccines	312
13.4.5	Transmission Blocking Vaccines (TBV)	313
13.4.6	Vaccines for <i>P. vivax</i>	314
13.5	Conclusions	314
	References	314
14	Toll-Like Receptor-Based Adjuvants: A Gateway Toward Improved Malaria Vaccination	319
	<i>Deepika Kannan, Arshpreet Kaur, Deepak B. Salunke, and Shailja Singh</i>	
14.1	Introduction	319
14.2	Host Immunological Responses in Malaria Conferring Protection	322
14.2.1	Innate Immunity	322
14.2.2	Adaptive Immunity	324
14.3	Crosstalk of PRRs in Host Immune System with Malarial Antigens	326
14.3.1	Glycosyl Phosphatidylinositols (GPI)	328
14.3.2	Plasmodial RNA	330
14.3.3	Hemozoin (Hz)	330
14.4	Synthetic TLR Adjuvants: An Approach to Enhance Vaccine Immunogenicity	331
14.4.1	TLR2	331
14.4.2	TLR4	333
14.4.3	TLR5	336
14.4.4	TLR7/8	337

14.4.5	TLR9	339
14.5	Conclusion	341
	Abbreviations	341
	References	342
15	Pure TLR7 Agonistic BBIQ is a Potential Adjuvant Against <i>Plasmodium berghei</i> ANKA Challenge <i>In Vivo</i>	353
	<i>Ruchika Saroa, Deepender Kaushik, Aruna Rakha, Upma Bagai, Sukhbir Kaur, and Deepak B. Salunke</i>	
15.1	Introduction	353
15.2	Material and Methods	354
15.2.1	Experimental Animals	354
15.2.2	Ethical Clearance	355
15.2.3	Parasite Infection	355
15.2.4	Isolation of Blood Stage Fraction	355
15.2.5	Adjuvant	355
15.3	Immunisation Protocol and Post-challenge Regime	356
15.4	Study Design	357
15.5	Isolation of Splenic Lymphocytes from Mice	357
15.6	FACS Analysis of Isolated Lymphocytes	357
15.7	IgG1 and IgG2a Antibody Response	357
15.8	Estimation of Various Cytokines	358
15.9	Statistical Analysis	358
15.10	Results and Discussion	358
15.10.1	Course of Infection	358
15.10.2	Flow Cytometric Analysis of Splenic T Cells and T reg Cells	358
15.10.3	Cytokine Profiling	360
15.10.4	Flow Cytometric Analysis of Splenic B Cells	362
15.10.5	IgG1 and IgG2a Response	362
15.11	Conclusion	363
	Conflict of Interests	364
	Funding	364
	Acknowledgment	364
	References	364
	Index	367